Two phase 3 trials of dronedarone, a novel class III antiarrhythmic agent currently in development worldwide, have demonstrated that the drug is safe and effective for the maintenance of normal sinus ...
Abstract and Introduction Evidence for a Proarrhythmic Effect of LV Pacing Evidence For an Antiarrhythmic Effect of CRT Conclusions References There are very few experimental studies that examined ...
HUYABIO Validates Protective Mechanism for Antiarrhythmic Drug HBI-3000 in AF Patients, Paving the Way for a New Era in Atrial Fibrillation Treatment PR Newswire SAN DIEGO, Nov. 14, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results